13/10/2026 SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D Legacy Healthcare received US FDA Breakthrough Therapy Designation for CINAINU® (LH-8) in alopecia areata Evergreen Therapeutics received FDA Fast Track Designation for EG-501 in NPSLE-CI SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D (Ref) SAB Biotherapeutics’ SAB-142 received US FDA Fast Track Designation for treatment of new-onset Stage 3 Type 1 diabetes (T1D). T